CN114096238A - 一种阿可拉定的纳米胶束制剂及其制备方法和用途 - Google Patents
一种阿可拉定的纳米胶束制剂及其制备方法和用途 Download PDFInfo
- Publication number
- CN114096238A CN114096238A CN202080044930.0A CN202080044930A CN114096238A CN 114096238 A CN114096238 A CN 114096238A CN 202080044930 A CN202080044930 A CN 202080044930A CN 114096238 A CN114096238 A CN 114096238A
- Authority
- CN
- China
- Prior art keywords
- preparation
- micelle
- solution
- alcaladine
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/2036—Silicones; Polysiloxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种阿可拉定的纳米胶束制剂,该制剂包括阿可拉定和聚合物辅料。还提供了这种纳米胶束制剂的制备方法。制备的阿可拉定的纳米胶束制剂具有生物利用度高的优点。
Description
PCT国内申请,说明书已公开。
Claims (19)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019106793090 | 2019-07-25 | ||
CN201910679309 | 2019-07-25 | ||
PCT/CN2020/104704 WO2021013262A1 (zh) | 2019-07-25 | 2020-07-26 | 一种阿可拉定的纳米胶束制剂及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114096238A true CN114096238A (zh) | 2022-02-25 |
Family
ID=74193135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080044930.0A Pending CN114096238A (zh) | 2019-07-25 | 2020-07-26 | 一种阿可拉定的纳米胶束制剂及其制备方法和用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220249370A1 (zh) |
EP (1) | EP4005561A4 (zh) |
JP (1) | JP7386967B2 (zh) |
KR (1) | KR20220061943A (zh) |
CN (1) | CN114096238A (zh) |
WO (1) | WO2021013262A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112294765A (zh) * | 2019-07-25 | 2021-02-02 | 北京盛诺基医药科技股份有限公司 | 一种阿可拉定的无定型及其制备方法和用途 |
CN114748447A (zh) * | 2022-03-14 | 2022-07-15 | 中国科学院华南植物园 | 一种淫羊藿素纳米粒及其制备方法和应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115350153A (zh) * | 2022-08-12 | 2022-11-18 | 青岛科技大学 | 一种紫檀芪纳米胶束制剂及其肝保护作用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013044734A1 (zh) * | 2011-09-28 | 2013-04-04 | 中国科学院深圳先进技术研究院 | 骨靶向脂质体及其制备方法 |
CN103860542A (zh) * | 2014-01-22 | 2014-06-18 | 贾晓斌 | 环淫羊藿苷元在制备抗肿瘤组合物中的应用 |
CN105476957A (zh) * | 2014-12-18 | 2016-04-13 | 北京珅奥基医药科技有限公司 | 一种阿可拉定注射剂及其制备方法和用途 |
CN108904447A (zh) * | 2018-08-15 | 2018-11-30 | 烟台大学 | 一种肝肿瘤靶向载体材料、胶束制剂及其制备方法 |
CN109464674A (zh) * | 2019-01-04 | 2019-03-15 | 湖北医药学院 | 羧基化聚乙二醇单甲醚-淫羊藿苷纳米粒子、制备方法及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003012505A (ja) | 2001-07-06 | 2003-01-15 | Nano Career Kk | 薬物含有高分子ミセルの凍結乾燥 |
CA2666587C (en) | 2006-10-20 | 2015-12-22 | Solvay Pharmaceuticals B.V. | Micellar nanoparticles of chemical substances |
CN110721156A (zh) * | 2018-06-29 | 2020-01-24 | 鲁南制药集团股份有限公司 | 一种淫羊藿苷元口服胶束制剂的制备方法 |
-
2020
- 2020-07-26 KR KR1020227002694A patent/KR20220061943A/ko active IP Right Grant
- 2020-07-26 WO PCT/CN2020/104704 patent/WO2021013262A1/zh active Application Filing
- 2020-07-26 EP EP20844154.3A patent/EP4005561A4/en active Pending
- 2020-07-26 US US17/629,177 patent/US20220249370A1/en active Pending
- 2020-07-26 CN CN202080044930.0A patent/CN114096238A/zh active Pending
- 2020-07-26 JP JP2022505252A patent/JP7386967B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013044734A1 (zh) * | 2011-09-28 | 2013-04-04 | 中国科学院深圳先进技术研究院 | 骨靶向脂质体及其制备方法 |
CN103860542A (zh) * | 2014-01-22 | 2014-06-18 | 贾晓斌 | 环淫羊藿苷元在制备抗肿瘤组合物中的应用 |
CN105476957A (zh) * | 2014-12-18 | 2016-04-13 | 北京珅奥基医药科技有限公司 | 一种阿可拉定注射剂及其制备方法和用途 |
CN108904447A (zh) * | 2018-08-15 | 2018-11-30 | 烟台大学 | 一种肝肿瘤靶向载体材料、胶束制剂及其制备方法 |
CN109464674A (zh) * | 2019-01-04 | 2019-03-15 | 湖北医药学院 | 羧基化聚乙二醇单甲醚-淫羊藿苷纳米粒子、制备方法及应用 |
Non-Patent Citations (1)
Title |
---|
SHAN SHIBING等: "Preparation of Icaritin-Loaded mPEG-PLA Micelles and Evaluation on Ischemic Brain Injury", 《JOURNAL OF BIOMEDICAL NANOTECHNOLOGY》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112294765A (zh) * | 2019-07-25 | 2021-02-02 | 北京盛诺基医药科技股份有限公司 | 一种阿可拉定的无定型及其制备方法和用途 |
CN114748447A (zh) * | 2022-03-14 | 2022-07-15 | 中国科学院华南植物园 | 一种淫羊藿素纳米粒及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
JP7386967B2 (ja) | 2023-11-27 |
EP4005561A1 (en) | 2022-06-01 |
EP4005561A4 (en) | 2022-12-07 |
US20220249370A1 (en) | 2022-08-11 |
KR20220061943A (ko) | 2022-05-13 |
JP2022542585A (ja) | 2022-10-05 |
WO2021013262A1 (zh) | 2021-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2322970C2 (ru) | Фармацевтические композиции, включающие коллоидную двуокись кремния | |
CN114096238A (zh) | 一种阿可拉定的纳米胶束制剂及其制备方法和用途 | |
JP4334869B2 (ja) | 溶解性または経口吸収性の改善された組成物 | |
TWI351969B (en) | Azithromycin dosage forms with reduced side effect | |
KR102241643B1 (ko) | 비정질 톨밥탄을 함유하는 경구 투여 현탁제 | |
KR100694667B1 (ko) | 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제 | |
CA3019257A1 (en) | A pharmaceutical formulation of palbociclib and a preparation method thereof | |
EP1741424B1 (en) | Solid pharmaceutical dispersions with enhanced bioavailabilty | |
EP1080721A2 (en) | Non-crystalline solid dispersant comprising cefuromixe axetil | |
EP0018773B1 (en) | A pharmaceutical composition containing bencyclane fumarate, a process for its preparation and an inclusion compound containing bencyclane fumarate | |
ES2248802T3 (es) | Procedimiento para producir preparaciones de flavanolignanos. | |
TW201919621A (zh) | 醫藥製劑 | |
EP4079295A1 (en) | Composition having improved solubility and bioavailability of olaparib | |
EP4257119A1 (en) | Olaparib solid dispersion composition with improved stability and bioavailability | |
KR20080045110A (ko) | 튜불린 억제제 인디불린의 경구용 고체 약제학적 제형 | |
US20210077451A1 (en) | A stable oral pharmaceutical composition of ferric citrate | |
AU2017256184A1 (en) | Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them | |
KR101555908B1 (ko) | 몬테루카스트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 액상 제제 및 이의 제조방법 | |
CN114129518A (zh) | 一种氟可拉定的纳米胶束制剂及其制备方法和用途 | |
WO2017153822A1 (en) | Resinates of pharamceutically acceptable salts of tofacitinib such as tofacitinib citrate, for taste masking | |
KR101118199B1 (ko) | 타크롤리무스를 가용화하기 위한 고분자 미셀 조성물 | |
CN113633620B (zh) | 一种含阿齐沙坦酯钾盐片剂及其制备方法 | |
CN103179953A (zh) | 含6’-氟-(n-甲基-或n,n-二甲基-)-4-苯基-4’,9’-二氢-3’h-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺的药物剂型 | |
WO1996039126A2 (en) | Ranitidine salts on magnesium trisilicate as an adsorbate | |
EP2558079B1 (en) | Ciprofloxacin dry syrup composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |